Scholarlink

<p>Congenital heart defects (CHDs), ranging from minor issues to critical malformations requiring urgent and ongoing medical care, are structural heart abnormalities present at birth. Historically, the prognosis for CHD patients was poor; however, advancements in medical treatments have significantly improved survival rates, with approximately 90% of children with CHDs now reaching adulthood. Standard CHD treatments include cardiac catheterization, heart surgery, medications, and, in severe cases, heart transplantation. Despite these advancements, innovative approaches are urgently needed to enhance therapeutic outcomes and overcome the limitations of current treatments. Recently, the integration of stem cell technologies with bio-scaffold engineering has garnered substantial attention. Key breakthroughs include the development of resilient biological scaffolds designed to expand and remodel within the heart, potentially overcoming the limitations of existing prostheses. Promising regenerative CHD treatments emerge from decellularized extracellular matrix scaffolds combined with autologous stem cells. Tissue engineering and pre-vascularization technologies aim to create functional heart tissues capable of growing with the child, thus reducing the need for multiple procedures. Enhanced scaffold fabrication techniques, such as 3D bioprinting, nanofiber scaffolds, and biomimetic fixation methods, have significantly advanced the field. These technologies enable better integration with native cardiac tissues and allow precise control over scaffold properties. Additionally, innovations in hybrid and smart scaffolds, along with bioreactor conditioning, further amplify the regenerative potential of engineered cardiac tissues. This review focuses on the convergence of stem cell therapy and bio-scaffold technology, highlighting the latest advancements in CHD treatment. It explores the evolution of novel materials and methodologies aimed at creating flexible, durable solutions for managing CHDs. By combining regenerative medicine with cutting-edge scaffold engineering, these emerging therapies offer hope for improved outcomes and quality of life for individuals affected by CHDs.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Advancing Congenital Heart Defect Treatments: Synergistic Approaches with Stem Cells and Functional Scaffolds

  • 期刊论文

  • 发表日期：

    2025年10月20日

查看全文
  • Zahra Sadat Razavi,
  • Hamed Afkhami

摘要

Congenital heart defects (CHDs), ranging from minor issues to critical malformations requiring urgent and ongoing medical care, are structural heart abnormalities present at birth. Historically, the prognosis for CHD patients was poor; however, advancements in medical treatments have significantly improved survival rates, with approximately 90% of children with CHDs now reaching adulthood. Standard CHD treatments include cardiac catheterization, heart surgery, medications, and, in severe cases, heart transplantation. Despite these advancements, innovative approaches are urgently needed to enhance therapeutic outcomes and overcome the limitations of current treatments. Recently, the integration of stem cell technologies with bio-scaffold engineering has garnered substantial attention. Key breakthroughs include the development of resilient biological scaffolds designed to expand and remodel within the heart, potentially overcoming the limitations of existing prostheses. Promising regenerative CHD treatments emerge from decellularized extracellular matrix scaffolds combined with autologous stem cells. Tissue engineering and pre-vascularization technologies aim to create functional heart tissues capable of growing with the child, thus reducing the need for multiple procedures. Enhanced scaffold fabrication techniques, such as 3D bioprinting, nanofiber scaffolds, and biomimetic fixation methods, have significantly advanced the field. These technologies enable better integration with native cardiac tissues and allow precise control over scaffold properties. Additionally, innovations in hybrid and smart scaffolds, along with bioreactor conditioning, further amplify the regenerative potential of engineered cardiac tissues. This review focuses on the convergence of stem cell therapy and bio-scaffold technology, highlighting the latest advancements in CHD treatment. It explores the evolution of novel materials and methodologies aimed at creating flexible, durable solutions for managing CHDs. By combining regenerative medicine with cutting-edge scaffold engineering, these emerging therapies offer hope for improved outcomes and quality of life for individuals affected by CHDs.